

References

I-194

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Muntoni F, Frank D, Sardone V, et al. Golodirsén Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations Amenable to Exon 53 Skipping (S22.001). *Neuro*. 2018;90(15 Supplement)
3. Vyondys 53™ (golodirsén) [package insert]. Cambridge, MA. Sarepta Therapeutics, Inc. 12/2019.
4. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Golodirsén.
5. Micromedex DrugDex Compendium®. 2020. Golodirsén.
6. Hayes, Inc. Hayes Emerging Technology Report. Vyondys (Golodirsén) for Duchenne Muscular Dystrophy. Lansdale, PA: Hayes, Inc.; December 2019.